FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379651211> ?p ?o ?g. }

• W4379651211 endingPage "1888" @default.
• W4379651211 startingPage "1887" @default.
• W4379651211 abstract "Background Patients with immune-mediated rheumatic diseases (IMRDs) have been prioritized for COVID-19 vaccination to mitigate the infection severity risks. Patients with rheumatoid arthritis (RA) are at a high risk of severe COVID-19 outcomes, especially those under immunosuppression or with comorbidities associated. However, few studies in the literature assessed the safety and immunogenicity of the COVID-19 heterologous vaccine schedules in patients with RA. Objectives Evaluate the safety and immunogenicity of two heterologous vaccine schedules against SARS-CoV-2 in patients with RA. Methods These data are from the study “SAFER - Safety and Efficacy on COVID-19 Vaccine in Rheumatic Diseases,” a Brazilian multicentric prospective phase IV study to evaluate COVID-19 vaccine in IMRDs in Brazil. Immunogenicity and adverse events (AEs) in patients with RA of all centers were assessed after two doses of ChAdOx1 plus additional dose of BNT162b2 or after two doses of inactivated SARS-CoV-2 vaccine CoronaVac plus additional dose of BNT162b2. The titers of neutralizing antibodies against the receptor-biding domain of protein spike (S) of SARS-CoV-2 (anti-RBD) were measured by chemiluminescence test after each dose of immunizers. Proportions between groups were compared using the chi-square and Fisher’s exact tests for categorical variables. Clinical Disease Activity Index (CDAI) before and after vaccination was assessed using the McNemar test. Results A total of 107 patients with RA were include in the study, most of them female, with a mean age of 46 years. Biological disease modifying anti-rheumatic drugs (DMARDs) were used by 50 % of the patients and conventional synthetics DMARDs in 48 %. Two doses of CoronaVac plus additional dose of BNT162b2 was used in 66 patients and two doses of ChAdOx1 plus additional dose of BNT162b2 in 41. Only mild AEs were observed, mainly after the first dose. The most common AEs after all doses, regardless of the immunizer type, were pain at the injection, headache, arthralgia and myalgia. ChAdOx1 had a higher frequency of pain at the injection (66% vs 32 %, p < 0,001) and arthralgia (68% vs 15%, p < 0,001) compared to CoronaVac. No patients had flare after the vaccination. The titers of anti-RBD after two doses of ChAdOx1 were higher compared to two doses of CoronaVac (6,03 BAU/mL vs 4,67 BAU/mL, p < 0,001). However, after the additional dose of BNT162b2, the anti-RBD titers were similar in both groups (7.28 BAU/mL vs 7.06 BAU/mL, p = 0.56). Only two cases of COVID 19, with mild symptoms, were reported, one in each group. Figure 1. Conclusion ChAdOx1, CoronaVac, and BNT162b2 vaccines are safe in RA patients. The frequency of local adverse effects, particularly pain at the injection site, is high. AEs are more frequent with ChAdOx1, especially after the first dose. The use of the immunizers does not change the degree of inflammatory activity of the disease. The immunogenicity of the two heterologous regimens analyzed was similar. References [1]Marques C, Kakehasi AM, Gomides APM, Paiva EDS, Dos Reis Neto ET, Pileggi GCS, et al. A Brazilian Cohort of Patients With Immuno-Mediated Chronic Inflammatory Diseases Infected by SARS-CoV-2 (ReumaCoV-Brasil Registry): Protocol for a Prospective, Observational Study. JMIR Res Protoc. [2]Medeiros-Ribeiro AC, Aikawa NE, Saad CGS, Yuki EFN, Pedrosa T, Fusco SRG, et al. Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial. Nat Med. 2021;27(10):1744-1751. [3]Machado PM, Lawson-Tovey S, Strangfeld A, Mateus EF, Hyrich KL, Gossec L, et al. Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry. Ann Rheum Dis. 2022;81(5):695-709. [4]Tavares ACFMG, Melo AKG, Cruz VA, Souza VA, Carvalho JS, Machado KLLL, et al. Guidelines on COVID-19 vaccination in patients with immunemediated rheumatic diseases: a Brazilian Society of Rheumatology task force. Adv Rheumatol. 2022;62:3. Acknowledgements: NIL. Disclosure of Interests None Declared." @default.
• W4379651211 created "2023-06-08" @default.
• W4379651211 creator A5000536567 @default.
• W4379651211 creator A5000676536 @default.
• W4379651211 creator A5001106269 @default.
• W4379651211 creator A5002120049 @default.
• W4379651211 creator A5003385320 @default.
• W4379651211 creator A5009353938 @default.
• W4379651211 creator A5009759975 @default.
• W4379651211 creator A5011619522 @default.
• W4379651211 creator A5012336852 @default.
• W4379651211 creator A5013694588 @default.
• W4379651211 creator A5015778336 @default.
• W4379651211 creator A5017523406 @default.
• W4379651211 creator A5019063068 @default.
• W4379651211 creator A5020233707 @default.
• W4379651211 creator A5024292944 @default.
• W4379651211 creator A5024581042 @default.
• W4379651211 creator A5028638086 @default.
• W4379651211 creator A5035203540 @default.
• W4379651211 creator A5035778990 @default.
• W4379651211 creator A5037307268 @default.
• W4379651211 creator A5038148752 @default.
• W4379651211 creator A5041094087 @default.
• W4379651211 creator A5041542496 @default.
• W4379651211 creator A5042863197 @default.
• W4379651211 creator A5043394966 @default.
• W4379651211 creator A5043662977 @default.
• W4379651211 creator A5046764799 @default.
• W4379651211 creator A5047171179 @default.
• W4379651211 creator A5052386622 @default.
• W4379651211 creator A5052433958 @default.
• W4379651211 creator A5054859400 @default.
• W4379651211 creator A5055245583 @default.
• W4379651211 creator A5058929547 @default.
• W4379651211 creator A5059287765 @default.
• W4379651211 creator A5060412981 @default.
• W4379651211 creator A5062489326 @default.
• W4379651211 creator A5067111992 @default.
• W4379651211 creator A5068301692 @default.
• W4379651211 creator A5070113489 @default.
• W4379651211 creator A5071110958 @default.
• W4379651211 creator A5071125674 @default.
• W4379651211 creator A5071489324 @default.
• W4379651211 creator A5072932215 @default.
• W4379651211 creator A5073505775 @default.
• W4379651211 creator A5073894036 @default.
• W4379651211 creator A5074198458 @default.
• W4379651211 creator A5074850636 @default.
• W4379651211 creator A5076561191 @default.
• W4379651211 creator A5078215396 @default.
• W4379651211 creator A5078750653 @default.
• W4379651211 creator A5079358705 @default.
• W4379651211 creator A5079572183 @default.
• W4379651211 creator A5080257414 @default.
• W4379651211 creator A5080488104 @default.
• W4379651211 creator A5081629766 @default.
• W4379651211 creator A5082221558 @default.
• W4379651211 creator A5085631855 @default.
• W4379651211 creator A5086232206 @default.
• W4379651211 creator A5086439582 @default.
• W4379651211 creator A5088667728 @default.
• W4379651211 creator A5092107472 @default.
• W4379651211 date "2023-05-30" @default.
• W4379651211 modified "2023-10-16" @default.
• W4379651211 title "AB1316 SAFETY AND IMMUNOGENICITY OF TWO HETEROLOGOUS VACCINE SCHEDULES AGAINST SARS-CoV-2 IN PATIENTS WITH RHEUMATOID ARTHRITIS: BRAZILIAN MULTICENTER STUDY" @default.
• W4379651211 doi "https://doi.org/10.1136/annrheumdis-2023-eular.4213" @default.
• W4379651211 hasPublicationYear "2023" @default.
• W4379651211 type Work @default.
• W4379651211 citedByCount "0" @default.
• W4379651211 crossrefType "journal-article" @default.
• W4379651211 hasAuthorship W4379651211A5000536567 @default.
• W4379651211 hasAuthorship W4379651211A5000676536 @default.
• W4379651211 hasAuthorship W4379651211A5001106269 @default.
• W4379651211 hasAuthorship W4379651211A5002120049 @default.
• W4379651211 hasAuthorship W4379651211A5003385320 @default.
• W4379651211 hasAuthorship W4379651211A5009353938 @default.
• W4379651211 hasAuthorship W4379651211A5009759975 @default.
• W4379651211 hasAuthorship W4379651211A5011619522 @default.
• W4379651211 hasAuthorship W4379651211A5012336852 @default.
• W4379651211 hasAuthorship W4379651211A5013694588 @default.
• W4379651211 hasAuthorship W4379651211A5015778336 @default.
• W4379651211 hasAuthorship W4379651211A5017523406 @default.
• W4379651211 hasAuthorship W4379651211A5019063068 @default.
• W4379651211 hasAuthorship W4379651211A5020233707 @default.
• W4379651211 hasAuthorship W4379651211A5024292944 @default.
• W4379651211 hasAuthorship W4379651211A5024581042 @default.
• W4379651211 hasAuthorship W4379651211A5028638086 @default.
• W4379651211 hasAuthorship W4379651211A5035203540 @default.
• W4379651211 hasAuthorship W4379651211A5035778990 @default.
• W4379651211 hasAuthorship W4379651211A5037307268 @default.
• W4379651211 hasAuthorship W4379651211A5038148752 @default.
• W4379651211 hasAuthorship W4379651211A5041094087 @default.
• W4379651211 hasAuthorship W4379651211A5041542496 @default.
• W4379651211 hasAuthorship W4379651211A5042863197 @default.
• W4379651211 hasAuthorship W4379651211A5043394966 @default.
• W4379651211 hasAuthorship W4379651211A5043662977 @default.
• W4379651211 hasAuthorship W4379651211A5046764799 @default.

• next